Does Embody GLP1 Work? What to Expect, When, and the Catch

Disclosure: Some links on this page are affiliate links, marked “Sponsored.” If you use one, we may earn a commission at no extra cost to you. It never changes our verdict. How we make money →

Does Embody GLP1 work? It may, but the strongest proof is for FDA-approved products—not Embody’s compounded injections. In large trials, the semaglutide and tirzepatide products studied helped people lose about 15% to 21% of their weight over 68 to 72 weeks. We found no public clinical trial of Embody’s finished compounded products.

The money decision is clearer. Embody’s current store lists one month of compounded semaglutide for $79 and compounded tirzepatide for $129. You pay at checkout before the final clinician decision, and Embody’s current policy says payments are generally final. That refund catch matters more than any before-and-after photo.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Embody may fit you if you:

• Plan to pay cash instead of billing insurance
• Are comfortable with a compounded weekly injection that is not FDA-approved
• Want a public one-month store price of $79 for semaglutide or $129 for tirzepatide
• Accept that the exact medicine, dose, pharmacy, and state availability depend on clinician review
• Can live with a strict no-change-of-mind refund policy

Skip Embody if you:

• Want an FDA-approved finished medicine or want help using insurance → compare the FDA-approved path
• Need a normal money-back promise if treatment does not help
• Want a currently verified needle-free Embody product
• Do not want to pay before the final clinician decision
• Are not comfortable checking a multidose vial, concentration, syringe units, and pharmacy label

Embody GLP1 in 30 seconds

Want to find out whether Embody serves you before you pay? Embody says its first two-minute screener does not require a card. If you continue to a paid plan, the charge happens at checkout before the final clinician decision, so read the total, term, and refund policy first. Take Embody’s no-card fit screener → (sponsored link)

What we actually checked On September 23, 2026, we checked Embody’s public store, home page, sale page, terms, refund policy, contact page, listed pharmacy partners, and Trustpilot profile. We compared the medical and regulatory claims with current FDA guidance, the STEP 1 and SURMOUNT-1 trial reports, current Wegovy prescribing information, and the Endocrine Society’s obesity-medication guideline. What we did not do: We did not buy a plan, receive care, time a shipment, test a vial, verify the contents of any patient’s medicine, or inspect Embody’s private checkout after entering personal health information. We also found no public clinical trial of Embody’s own finished compounded products.

Does Embody GLP1 work? It depends on what “work” means

“Does Embody work?” is really three questions: can the products studied in major trials cause weight loss, has Embody’s own finished product been tested, and will one person respond well enough to keep using it? The answer is yes to the first, unknown for Embody’s specific product, and personal for the third.

Here is the proof, stacked from strongest to weakest.

The evidence ladder: what is proven and what is not

Sources: STEP 1, SURMOUNT-1, the 2026 self-pay telehealth preprint, and Embody’s current public disclosures.

Why “I lost 30 pounds” cannot settle it

A great review feels like proof. It is not. Two people using an Embody plan may have different prescriptions, doses, concentrations, pharmacies, starting weights, side effects, eating patterns, and refill timing. There is no control group. People who stop early may also be less likely to post a long success story.

That is why the ladder ranks randomized trials first and customer stories last.

Our verdict in one line: The approved semaglutide and tirzepatide products studied in large trials have strong evidence. Embody’s specific compounded finished products do not have public trial evidence of their own. That gap is the real question.

Is Embody’s medicine real, and is it FDA-approved?

Embody says licensed clinicians may prescribe compounded semaglutide or tirzepatide that is prepared by a state-licensed 503A pharmacy for an individual patient. Those finished compounded products are not FDA-approved, are not FDA-approved generics, and are not Wegovy or Zepbound.

A few quick definitions matter here:

• Compounded means a pharmacy prepares a prescription for an individual patient under compounding rules. The finished product does not have FDA approval.
• A 503A pharmacy is generally overseen by a state board of pharmacy and compounds for individual patients based on prescriptions. Embody says its partners operate in this category.
• A 503B outsourcing facility is a different federal category that can compound larger batches under separate rules. Embody’s public pages describe its partners as 503A pharmacies, not 503B facilities.

Embody’s current public store lists compounded injections. It does not list FDA-approved Wegovy, Zepbound, Foundayo, or another brand-name weight-loss product for purchase through its store.

Who does what at Embody

Sources: Embody’s terms, current home-page disclosures, and current partner list.

How Embody compares with the FDA’s seven online-buying red flags

The FDA lists seven signs that should make a buyer slow down. This is not an FDA score, approval, or endorsement of Embody. It is a reader checklist based on what Embody currently publishes and what still has to be checked after a prescription ships.

FDA source: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

Is compounded GLP-1 still legal in 2026?

Patient-specific compounding can still be lawful, but the shortage-era lane for routinely making copies of semaglutide and tirzepatide is over. FDA says a 503A pharmacy generally cannot compound products that are essentially copies of commercially available drugs regularly or in large amounts unless a prescriber documents a change that creates a significant difference for an identified patient.

The shortage-based enforcement windows ended in 2025. FDA’s April 2026 update says semaglutide and tirzepatide are not on the drug-shortage list or the 503B bulks list. In April 2026, FDA also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the agency said it would consider comments before a final decision.

That does not let a public review decide whether one patient’s prescription is lawful or medically needed. Ask the prescribing clinician what patient-specific need supports the compound and which pharmacy will fill it.

Sources: FDA’s April 2026 compounding update and the 503B bulks-list proposal.

The one catch that matters most

Here is what you should know before anything else. Embody does not sell an FDA-approved finished medicine through its current public store. FDA says compounded products should be used only when a patient’s medical needs cannot be met by an FDA-approved drug.

If FDA approval or insurance is your top priority, Embody is the wrong path. Ro is a better fit because it offers access to FDA-approved options and insurance support.

But if you and a licensed clinician decide a patient-specific compounded prescription is appropriate, Embody’s current store price is much lower than many approved cash-pay products, and Embody says the price does not rise when the dose changes within the same medicine and treatment plan. The catch is that its public pages do not agree cleanly on the exact price and term, so the checkout screen matters.

Need an FDA-approved medicine or insurance help instead? Ro currently lists FDA-approved options including the Wegovy pill, Wegovy injection, Foundayo pill, and Zepbound KwikPen. Membership starts at $39, then runs from $74 per month with an annual prepaid plan to $149 month-to-month. Medication is billed separately. See Ro’s FDA-approved treatment options → (sponsored link)

Not sure which way to go? The right GLP-1 provider is not the same for everyone—it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path such as injection or oral medication, and your budget. Because a general answer cannot resolve those for you, use The RX Index’s Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

How much weight do people lose on Embody?

No public Embody-only clinical results let an outside reader predict an Embody outcome. In STEP 1, semaglutide 2.4 mg produced 14.9% average weight loss over 68 weeks. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% average weight loss over 72 weeks. Those are trial averages for specific products and protocols—not a promise for an Embody compound.

Percentages are hard to picture, so we converted the trial averages into pounds. The 5% column is a useful reference point, not a deadline or a personal forecast.

What the trial averages look like in pounds

The RX Index calculation using the 14.9% STEP 1 and 20.9% SURMOUNT-1 treatment-policy averages. The trials did not test Embody’s finished products, and this table is not a prediction.

What the 5% number does—and does not—tell you

Multiply your starting weight by 0.05 to see what 5% means in pounds. For a 220-pound person, it is 11 pounds.

An older Endocrine Society guideline uses 5% after three months as a general way to review whether a weight-loss medicine is effective and safe. That guideline was published before today’s semaglutide and tirzepatide obesity programs and before their slow dose-escalation schedules became common. It should not be used as an automatic internet pass/fail test for an Embody patient who may still be moving through lower doses.

Use 5% as one discussion point. Ask your clinician to consider your current dose, time at that dose, tolerability, missed doses, refill gaps, and overall trend.

Not everyone reaches the average

In STEP 1, 86.4% of participants receiving semaglutide reached at least 5% weight loss, versus 31.5% with placebo. In SURMOUNT-1, 85%, 89%, and 91% of participants receiving 5, 10, and 15 mg of tirzepatide reached at least 5%, versus 35% with placebo.

Those numbers tilt the odds. They do not guarantee one person’s result, and they do not validate an untested finished compound.

What about people outside clinical trials?

The 2026 self-pay telehealth preprint is interesting because it looked at a setting closer to online cash-pay care. But it only included 572 people who completed at least nine months of follow-up out of a much larger starting population. It mixed branded and compounded products, used self-reported weights, was funded by CareValidate, included a CareValidate employee as an author, and had not been peer-reviewed when we checked it.

That makes it useful for one narrow point: some long-term self-pay telehealth patients lose meaningful weight. It does not tell us what an average Embody starter should expect.

How long does Embody take to work?

There is no verified Embody-only timeline that applies to everyone. Embody’s sale-page FAQ describes a common semaglutide plan of 0.25 mg weekly for four weeks, then 0.5 mg for eight weeks, while the current Wegovy label moves from 0.5 mg to 1 mg at week nine. That mismatch is one reason to get your own schedule in writing.

These are different finished products, so the Wegovy label is not an Embody dosing instruction. The comparison only shows why “judge it at exactly 12 weeks” can be too simple.

Embody’s public semaglutide schedule versus the Wegovy label

Sources: Embody’s public sale-page FAQ and the current Wegovy prescribing information.

One Embody FAQ line says doses increase every four weeks, while its displayed semaglutide table keeps 0.5 mg for eight weeks. Do not guess which statement applies to you. Ask for the medication name, concentration, weekly amount, syringe units, and next review date in writing.

What you may notice first

Some people report appetite changes before large scale changes. Nausea and other stomach symptoms are common with approved GLP-1 medicines, especially during dose escalation. That does not mean every symptom is normal or safe to ignore.

Message your clinician if side effects make it hard to eat, drink, or follow the plan. Do not change the dose on your own.

If you are prescribed tirzepatide

Embody’s public tirzepatide dose table is not clear enough to use: it displays malformed “10/mg” and “20/mg” entries. The current Zepbound label uses 2.5 mg as an initiation dose and then increases in 2.5 mg steps based on response and tolerability. Those are Zepbound instructions, not instructions for an Embody compound.

Get your own tirzepatide concentration, amount in milligrams, syringe units, and escalation plan directly from the prescriber and dispensing pharmacy.

Want to test Embody without locking up a year of payments? If the current one-month store price stayed the same for three purchases, three semaglutide months would total $237. The three-month prepay is $228. That is only a $9 difference for keeping control of the next renewal. Tirzepatide has the same $9 difference: $387 at three current one-month prices versus $378 prepaid. Check Embody’s live one-month option → (sponsored link)

We checked 9 Embody claims. Here is what held up.

We compared nine current Embody marketing claims with its own terms and refund policy, FDA guidance, the major trials, and its live Trustpilot profile on September 23, 2026. Some claims hold up as provider-stated program facts. Several need major context. Two outcome claims do not hold up as written.

Sources: Embody’s sale page, store, terms, refund policy, Trustpilot, FDA guidance, STEP 1, and SURMOUNT-1.

The three public price stories do not match

This is the original check most Embody reviews miss.

What this tells you: Embody’s headlines run ahead of the proof, and its public pricing pages do not tell one clean story. But the store totals, legal operator, clinician network, pharmacy list, compounded-drug disclosure, and refund rules are public. Judge the offer by the checkout total, plan length, order confirmation, pharmacy, and current policy—not one banner.

Now you know what to check. See the live offer without trusting the headline alone. Screenshot the medication, total due today, term length, renewal date, renewal amount, cancellation deadline, and refund-policy date before submitting payment. See Embody’s current checkout path → (sponsored link)

What makes Embody work—or stall—for real people?

A prescription cannot help if the refill is late, the dose instructions are unclear, the vial arrives warm, or side effects make treatment impossible to continue. Recent Embody reviews focus heavily on enrollment, clinician access, refill communication, shipment timing, billing, and support. Those are service signals, not proof about the medicine itself.

We matched the common review themes with practical checks. These are individual reports and Trustpilot’s summary, not failure rates.

Check these six things when your box arrives

The FDA warns about dosing mistakes, warm shipments, and fraudulent labels with compounded injectable GLP-1 products. One minute of checking can catch a serious problem.

1. Check the storage condition. If an injectable GLP-1 arrives warm or without enough refrigeration, FDA recommends not using it. Contact the pharmacy.
2. Read the full label. It should show your name, medicine, concentration, directions, pharmacy, and a way to contact the pharmacy.
3. Verify the pharmacy. Match the name and address against the pharmacy’s current state-board record and your order confirmation.
4. Check the ingredient wording. FDA says semaglutide sodium and semaglutide acetate are different ingredients from the ingredient used in approved semaglutide products and says it is not aware of a lawful basis for using those salt forms in compounding.
5. Know both milligrams and syringe units. If the label or supplied syringe leaves any doubt, ask the prescriber or pharmacy before injecting.
6. Date a multidose vial when first used. FDA currently recommends discarding a multidose sterile vial within 28 days after first use and using a new sterile needle and syringe for every dose.

Print or screenshot this checklist before your first shipment.

What do Embody reviews say about results and service?

Embody had a 3.8 out of 5 Trustpilot rating from 8,368 reviews when we checked on September 23, 2026. The profile’s current split was 61% five-star and 24% one-star. Positive themes center on easy enrollment and helpful providers; negative themes center on support delays, shipping, refill communication, unexpected charges, and package problems.

In their words

“I like the ease of the system…” — Erica K., four stars, invited Trustpilot review

“The chat service is very poor…” — VH, four stars, invited Trustpilot review

The first reviewer also wanted a clearer refill reminder. The second said email support was good but wanted a dose change explained before it happened.

These are service experiences, not evidence that Embody’s medicine will work for you. “Invited” means Embody asked the customer to leave a review. Trustpilot also states that reviews are user opinions and it does not fact-check the medical claims inside them.

For billing, cancellation, complaint themes, and the full provider verdict, read our Embody GLP1 review.

Does the Embody GLP-1 gum work?

Current availability is not clear enough to promise. Embody’s live store listed 14 products when we checked, and every visible product was an injection. Its April terms still mention semaglutide and tirzepatide gum, but we found no current public gum product in the store and no Embody-specific clinical evidence for a gum.

That is another public-page conflict—not proof that gum can never be prescribed. If an old ad, review, or internal RX Index page led you to Embody for gum, ask support for all of this in writing before paying:

• The exact product page
• Whether the gum is currently available in your state
• The prescribing clinician and dispensing pharmacy
• The ingredients, concentration, and dosing directions
• The total price and renewal price
• The evidence the clinician uses when discussing expected results

Do not call an Embody gum the same as an FDA-approved oral product. They are different products with different approval and evidence histories.

If needles are the dealbreaker, FDA-approved pills now include the Wegovy pill and Foundayo. Ro currently lists both, with starter medication prices from $149 per month; its membership is extra.

Want an FDA-approved pill instead of a compounded shot? Ro’s first month of membership is $39. Ongoing membership is $149 month-to-month or as low as $74 per month with an annual prepaid plan. Medication is billed separately, and current starter prices begin at $149 for the Wegovy pill or Foundayo if prescribed. See FDA-approved pill options on Ro → (sponsored link)

Can you get your money back if Embody does not work?

No. Embody’s refund policy, last updated August 25, 2026, says there is no guarantee of results and all payments are final at purchase. The sole stated exception is provider-initiated medical disqualification, and Embody may subtract the value of services already provided.

Better to know this before checkout than at month two.

Source: Embody Subscription Services Cancellation & Refund Policy, last updated August 25, 2026.

When exactly do you pay?

Embody’s current public flow separates the free first screener from the paid program:

1. Take the short health screener without a card.
2. If the screen does not exclude you, choose a program.
3. Pay at checkout.
4. Complete the fuller medical intake in the portal.
5. A licensed clinician makes the final prescription decision.
6. If medically appropriate, the prescription goes to a pharmacy.

So “no card needed to see whether you may fit” is true for the first screener, but “you pay only after final approval” is not.

What each current store plan costs

Current Embody store totals checked September 23, 2026. Exact checkout terms can change.

The $9 safety net

If the current one-month semaglutide price stayed at $79 for three purchases, the total would be $237. The three-month prepay is $228. That is a $9 savings for giving up the option to stop the next monthly renewal.

For tirzepatide, three purchases at the current $129 one-month price would total $387, versus $378 prepaid. Again, the difference is $9.

At today's store prices, the 12-month totals are $120 below 12 one-month purchases for either medication. Prices can change, so treat that as dated arithmetic—not a promise about future renewals. A long prepay can make sense after you understand the product, service, and response. It is a poor first move if you still need to learn whether Embody fits you.

Do not assume the $69 or $119 headline is month-to-month

Embody’s sale page calls $69 and $119 flat monthly prices and also uses “no contracts” language. Its store pairs those figures with the 12-month totals of $828 and $1,428. Its April terms show older prices and programs.

That is too much conflict to solve by guessing. Before paying, screenshot:

• Medicine and formulation
• Full amount due today
• Number of weeks or months purchased
• Renewal amount and date
• Whether the plan automatically renews
• Cancellation method and 72-hour deadline
• Refund-policy date
• Any note that price can vary by medicine or pharmacy

Protect yourself in five steps

1. Start with the shortest term while you learn how the service and treatment fit you.
2. Screenshot the checkout before paying.
3. Set a reminder at least four days before billing. The policy requires 72 hours.
4. Cancel in writing through the portal or support, and save the confirmation.
5. Contact support about an error before filing a card dispute, as Embody’s policy requests.

Comfortable with the rules? Keep the first commitment small. Use the free first screener. If you continue, choose the one-month option only after the checkout clearly shows the medicine, total, term, and renewal you expect. Check Embody’s live terms and one-month price → (sponsored link)

What should you do if Embody is not working?

First, do not decide from one weigh-in or one internet deadline. Check how long you have been treated, the dose and concentration on your label, refill gaps, missed doses, side effects, and how long you have been at the clinician-selected dose. Then ask the clinician to review the full pattern.

Copy and send this to your Embody clinician

“Hi, I started [medicine] on [date]. My label says [concentration], and my current weekly amount is [milligrams and syringe units]. My starting weight was [X], and my current weight is [Y]. I have missed [number] doses and had [side effects or refill gaps]. Can we review whether my current plan, dose stage, and next refill still make sense?”

The Progress Checker above can fill in the weight math without judging your treatment.

Questions to discuss if progress is still limited

• Is the current dose stage still an initiation or escalation stage?
• Were there missed doses, late refills, or storage problems?
• Are side effects limiting nutrition, fluids, or adherence?
• Is the prescription concentration and measuring method clear?
• Is another medication or an FDA-approved treatment path medically appropriate?
• Would a different care model provide clearer follow-up or more reliable refills?

Never change a dose or switch medicines on your own.

Get urgent medical help for severe symptoms. The approved Wegovy and Zepbound labels warn about serious problems including pancreatitis, gallbladder disease, severe allergic reactions, and dehydration-related kidney injury. Call 911 for signs of a severe allergic reaction or another emergency. Contact your clinician promptly for severe or lasting stomach pain, repeated vomiting, inability to keep fluids down, yellow skin or eyes, or other serious symptoms.

See the current Wegovy prescribing information and Zepbound prescribing information for complete approved-product warnings. These labels are not labeling for an Embody compound, but they are authoritative sources for the approved products.

Is Embody worth it compared with FDA-approved options?

Embody may fit a cash-pay reader who accepts a patient-specific compounded injection, strict refund terms, and a plan that is not billed to insurance. An FDA-approved path fits better if you want a finished product reviewed by FDA, an approved pill, insurance help, or no membership charge unless you are eligible.

What a month costs

Sources: Embody store and Ro’s current weight-loss pricing, checked September 23, 2026. Promotions, doses, and eligibility can change.

Which path fits your situation?

How Embody reads across the five RX Index Score pillars

This is a qualitative read, not a new numerical score. See our methodology.

If the Embody fit sounds like you, take the low-risk next step—not the longest commitment. Use the no-card screener, then confirm the one-month checkout total, medicine, state, term, and refund policy before paying. See whether Embody fits your situation → (sponsored link) Prefer an FDA-approved path? Compare Ro’s approved options → (sponsored link)

How we checked Embody

We read Embody’s current store, home page, sale page, terms, contact page, partner disclosures, and August 25 refund policy on September 23, 2026. We compared those claims with FDA guidance, current approved-drug labels, STEP 1, SURMOUNT-1, the Endocrine Society guideline, a self-pay telehealth preprint, and Embody’s live Trustpilot profile.

• Who: The RX Index Editorial Team. No medical reviewer reviewed this page, so we do not claim one did.
• How: We used provider pages for current commercial facts, FDA and approved labels for regulatory and safety facts, original trial reports for clinical results, and Trustpilot only for service experience.
• Why: Search results often blend trial data, company claims, customer stories, and personal outcomes as if they are equal. This page separates them.
• What would change our conclusion: A public Embody-specific trial, a new FDA action, a new refund policy, corrected terms, a clear state list, or a material price change.
• How often: We recheck prices, products, state availability, policies, regulatory status, and Trustpilot monthly. We update the visible date only after checking them again.

Read our full methodology and editorial standards.

Embody GLP1 FAQ

Does Embody GLP1 actually work?

It may help an eligible patient, but no public Embody-specific clinical trial proves the result. STEP 1 and SURMOUNT-1 found about 15% to 21% average weight loss with the specific semaglutide and tirzepatide products studied over 68 to 72 weeks. Embody’s finished compounded injections were not tested in those trials.

How much weight can you lose with Embody?

There is no verified Embody average an outside reader can rely on. The major trial averages were 14.9% for semaglutide 2.4 mg at 68 weeks and 20.9% for tirzepatide 15 mg at 72 weeks. Those numbers are not a promise for an Embody compound or for one person.

How long does it take for Embody to start working?

There is no single verified Embody timeline. Embody’s public semaglutide FAQ describes 0.25 mg for four weeks and 0.5 mg for the next eight weeks for many patients, so some people may still be at a lower dose after 12 weeks. Ask your clinician when your exact prescription should be reviewed.

Is Embody’s semaglutide real?

Embody says licensed clinicians prescribe compounded semaglutide that is prepared by state-licensed 503A pharmacies. That is a prescription claim, not FDA approval or proof of the contents of one shipment. Check your own prescriber, pharmacy, label, concentration, and directions.

Is Embody FDA-approved?

No. Embody is a telehealth platform, and its current public store sells compounded semaglutide and tirzepatide products. Those finished compounded products are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.

Is compounded semaglutide as good as Wegovy?

No public head-to-head trial we found compares Embody’s finished compounded semaglutide with Wegovy. Wegovy is an FDA-approved finished product with product-specific trial and manufacturing evidence. An Embody compound is a different finished product and should not be presented as equal.

Does the Embody GLP-1 gum work?

Current availability is unclear. Embody’s live store showed 14 injection listings and no gum product on September 23, 2026, while its older April terms still mentioned gum. We found no public Embody-specific clinical trial of a gum. Get the exact product, pharmacy, evidence, and price in writing before paying.

Why am I not losing weight on Embody?

Possible reasons include still being at an initiation dose, refill gaps, missed doses, side effects, unclear measuring instructions, or simply needing more time at the clinician-selected dose. Do not use a single 12-week number to diagnose the problem. Ask the clinician to review the full timeline and label.

Can I get a refund if Embody does not work?

No. Embody’s August 25, 2026 policy says there is no guarantee of results and payments are generally final. The only stated exception is provider-initiated medical disqualification, with services already provided deducted from the refund.

Does Embody charge before final approval?

Yes. Embody says the first quick screener does not require a card. If you continue, payment happens at checkout before the licensed clinician completes the final prescription review.

Does Embody raise the price when the dose goes up?

Embody’s current home page says the price does not increase when the dose changes within the same medicine and treatment plan. Its terms also say a final charge may vary by prescribed medicine and pharmacy. Confirm the actual checkout and order confirmation rather than relying on one sentence.

Is the $69 Embody price real?

It is a live advertised figure, but the public pages do not explain it cleanly. The store’s 12-month semaglutide total is $828, which equals $69 per month, while the sale page presents $69 beside “no contracts” language. The one-month store price is $79. Check the total and term at checkout.

Can I cancel Embody anytime?

You can request cancellation anytime, but it only stops future billing. Embody must receive the request at least 72 hours before the next billing date to stop that charge. Prior payments and unused prepaid months are generally nonrefundable.

What states does Embody serve?

Its public pages conflict. The sale-page FAQ says all states except Louisiana, with Nebraska limited to age 19 and older. The terms say services are available only in certain states, and product pages say availability may vary. Confirm your state through the no-card screener or support before paying.

Is Embody legit?

Embody is a real operating platform run by Modern Metabolic Medicine, Inc. It names OpenLoop Health and four pharmacy partners. “Real company” does not mean the finished medication is FDA-approved, that every shipment is problem-free, or that the program fits every patient.

The bottom line

Embody may work for an eligible patient, but the public evidence does not prove an Embody-specific result. The approved semaglutide and tirzepatide products studied in major trials produced large average weight loss. Embody’s compounded finished products have no public clinical trial of their own, its marketing makes claims its own fine print cannot fully support, and its current refund policy gives you almost no room to change your mind after paying.

The good part is concrete: Embody names the company, clinician network, and pharmacy partners; publishes the compounded-drug disclosure; lists low current store totals; and offers a no-card first screener. The smart move is not blind trust or automatic rejection. It is to keep the first commitment small, screenshot the exact checkout, verify the prescription and pharmacy, get the dose and refill plan in writing, and review progress with the clinician instead of using one internet deadline.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

The RX Index: Independent guidance for choosing your GLP-1 path. We score providers and treatment paths on what actually matters—clinical legitimacy, care quality, transparency, access, and cost—then help you decide where to start.

Keep reading

• Embody GLP1 review: cost, complaints, and verdict
• What GLP-1 does Embody use?
• Embody GLP-1 alternatives
• Compounded GLP-1 enforcement tracker
• GLP-1 side-effects comparison chart
• Find My GLP-1 Path

Sources

Commercial facts checked September 23, 2026, unless noted.

Clinical and regulatory primary sources

1. Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1). New England Journal of Medicine, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1). New England Journal of Medicine, 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
3. Endocrine Society. “Pharmacological Management of Obesity Guideline Resources.” https://www.endocrine.org/clinical-practice-guidelines/pharmacological-management-of-obesity
4. FDA. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. FDA. “FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.” https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
6. FDA. “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List.” https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
7. FDA. “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s.” https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
8. Wegovy prescribing information, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
9. Zepbound prescribing information, Lilly. https://pi.lilly.com/us/zepbound-uspi.pdf

Real-world evidence

1. Patil P, et al. “Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long-Term GLP-1 Receptor Agonist Treatment of Self-Pay Patients.” medRxiv preprint, March 30, 2026. https://www.medrxiv.org/content/10.64898/2026.03.27.26349009v1

Embody current pages

1. Embody home page and disclosures. https://joinem.co/
2. Embody store catalog. https://joinem.co/collections/all
3. Embody sale page and FAQ. https://exclusive.joinem.co/
4. Embody Terms & Conditions, last updated April 24, 2026. https://joinem.co/pages/terms-conditions
5. Embody Subscription Services Cancellation & Refund Policy, last updated August 25, 2026. https://joinem.co/pages/refund-policy
6. Embody contact page. https://joinem.co/pages/contact

Reviews and FDA-approved alternative pricing

1. Embody on Trustpilot. https://www.trustpilot.com/review/joinem.co
2. Ro weight-loss pricing. https://ro.co/weight-loss/pricing/

This page gives general information, not medical advice. A licensed clinician must decide whether any prescription is appropriate. Prices, products, availability, and policies can change; confirm them before paying.